| Outcome Measures: |
Primary: Area under the drug concentration curve, To evaluate bioequivalence between formulation 2 and formulation 3 of MEDI0382, 48 hours|Maximum observed plasma concentration of MEDI0382, To evaluate bioequivalence between formulation 2 and formulation 3 of MEDI0382., 48 hours | Secondary: Area under the plasma drug concentration versus time curve from zero to infinity and to last observation, To compare the pharmacokinetic (PK) profiles of MEDI0382 formulation 2 versus formulation 3., 48 hours|Time to maximum observed plasma drug concentration, To compare the pharmacokinetic (PK) profiles of MEDI0382 formulation 2 versus formulation 3., 48 hours|Terminal phase elimination half-life, To compare the pharmacokinetic (PK) profiles of MEDI0382 formulation 2 versus formulation 3., 48 hours|Apparent clearance, To compare the pharmacokinetic (PK) profiles of MEDI0382 formulation 2 versus formulation 3., 48 hours|Adverse Events, To evaluate the safety and tolerability of a single dose of MEDI0382 in formulation 2 and 3., 38 days|12 lead electrocardiogram including RR, PR, QRS, QT, and QTc intervals, To evaluate the safety and tolerability of a single dose of MEDI0382 in formulation 2 and 3., 38 days|Anti-drug antibody titer, To evaluate the immunogenicity of a single dose of MEDI0382 in formulation 2 and 3., 38 days|Vital signs (temperature), To evaluate the safety and tolerability of a single dose of MEDI0382 in formulation 2 and 3, 38 days|Anti-drug antibody incidence, To evaluate the immunogenicity of a single dose of MEDI0382 in formulation 2 and 3., 38 days|Clinical laboratory assessments (hematology), To evaluate the safety and tolerability of a single dose of MEDI0382 in formulation 2 and 3, 38 days|Vital signs (systolic and diastolic blood pressure), To evaluate the safety and tolerability of a single dose of MEDI0382 in formulation 2 and 3., 38 days|Vital signs (pulse rate and respiratory rate), To evaluate the safety and tolerability of a single dose of MEDI0382 in formulation 2 and 3, 38 days|Clinical laboratory assessments (serum chemistry), To evaluate the safety and tolerability of a single dose of MEDI0382 in formulation 2 and 3, 38 days|Clinical laboratory assessments (urinalysis), To evaluate the safety and tolerability of a single dose of MEDI0382 in formulation 2 and 3, 38 days
|
